Loading company…
Meddenovo uses AI and molecular modeling to support drug discovery, particularly for cyclic peptides.
Founded in 2021 and based in Lyon, France, Meddenovo Drug Design applies computational biochemistry to pharmaceutical research. It offers in silico testing, drug design, and peptide databases, with a focus on cyclic peptides. In July 2024, ACT Venture Partners led EUR 1 million in pre-seed funding. The company plans to use the funding to develop its AI tools and expand research and partnerships.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in